Committee advances resolution urging PHP coverage of bioidentical hormones

The sponsor (identified in the transcript as the presenter for HCR10) told the committee that private health plans (PHP) already cover hormone treatment for menopausal symptoms and that HCR10 would ensure coverage for modern bioidentical hormones, which the sponsor described as having different safety and receptor-binding properties than older synthetic formulations. The sponsor said the fiscal note on the bill is zero and that the change is not expected to increase costs.

No public commenters opposed the resolution in committee and members asked only clarifying questions about availability and cost. The committee voted to favorably recommend HCR10 to the full body by voice vote; the transcript records the recommendation as unanimous but does not list numeric vote counts.